The Cat Health Company
Cat Health, feline longevity biotech, designs medicines addressing molecular aging mechanisms in cats; some programs reach clinical stages and out-licensing.
- Bucharest, Sector 1, RORomania
Cat Health, feline longevity biotech, designs medicines addressing molecular aging mechanisms in cats; some programs reach clinical stages and out-licensing.
thecathealth.comCrawled Nov 4, 2026
The Cat Health Company develops AI-driven biotech therapeutics to extend feline healthspans and advance veterinary medicine.
The Cat Health Company applies biotech and AI to advance feline health in the United States.
The Cat Health Company offers biotech care and wellness solutions to extend cats’ healthspans.
The company provides biotech and machine learning tools for veterinarians to implement feline longevity and precision care protocols.
The Cat Health Company USA develops biotech and AI solutions for cat health.
Understanding the Importance of Feline Safety in Clinical Trials Clinical trials are a crucial aspect of veterinary medicine, allowing researchers to devel
The Cat Health Company employs veterinary experts, AI researchers, and biotech scientists to advance feline longevity and care.
The Cat Health Company combines biotech, pharma, and machine learning to improve feline health and longevity.
The Cat Health Company applies biotech and AI to transform feline healthcare.
The Cat Health Company uses AI and biotech to improve cat healthcare in the United States.
Dr. Matt Kaeberlein, a pioneer in companion-animal aging research, joins The Cat Health Company’s Scientific Advisory Board. His decades of expertise in aging science support the company’s focus on feline health. The move aligns with The Cat Health Company’s mission to extend and improve the lives of cats through scientific innovation.
Sep 2026MENAFNNews article
The Cat Health Company (TCHC) collaborates with Ad Atomica to integrate AI-driven de novo drug discovery into its platform. This partnership introduces novel small-molecule approaches, expanding TCHC’s drug-discovery capabilities beyond its existing internal methods. The move aims to enhance the scope and potential of its drug development pipeline.
Sep 2026The National Law ReviewNews article
TCHC’s drug **PURR-001** demonstrates efficacy in a placebo-controlled study, increasing body mass and muscle thickness in cats with sarcopenia. The company secures its first European licensing agreement, advancing the treatment toward commercialization.
Sep 2026Longevity.TechnologyNews article
The Cat Health Company demonstrates **PURR-001** delivers measurable skeletal muscle improvement in a placebo-controlled trial of 35 geriatric cats. The asset shows promise in advancing toward manufacturing. Results highlight potential for addressing age-related muscle decline in feline patients.
Sep 2026Pet AgeNews article